X. Qi

发表

Self-Illuminating Triggered Release of Therapeutics from Photocleavable Nanoprodrug for the Targeted Treatment of Breast Cancer.

Dinglin Zhang, Wenhao Shen, F. Sun, 2022, ACS applied materials & interfaces.

Identification of prognostic indicators, diagnostic markers, and possible therapeutic targets among LIM homeobox transcription factors in breast cancer

Yi Zhang, J. Gu, Zaihui Peng, 2022, Cancer innovation.

Lobaplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: a 5-year follow-up of a randomized, open-label, phase II trial

Yi Zhang, Peng Tang, Shushu Wang, 2022, Therapeutic advances in medical oncology.

Integrated endotoxin-adsorption and antibacterial properties of platelet-membrane-coated copper silicate hollow microspheres for wound healing

Xuntao Yin, Long Yuan, Zaihui Peng, 2021, Journal of nanobiotechnology.

Dramatic Response to Pyrotinib and T-DM1 in HER2-Negative Metastatic Breast Cancer With 2 Activating HER2 Mutations

Long Yuan, Yi Zhang, Qiyun Shi, 2023, The oncologist.

Sensitive Activatable Nanoprobes for Real‐Time Ratiometric Magnetic Resonance Imaging of Reactive Oxygen Species and Ameliorating Inflammation In Vivo

G. Luo, Xiao-rong Zhang, Tengfei Liu, 2022, Advanced materials.

Correlation between androgen receptor expression and pathological response rate in pre-operative HER2-positive breast cancer patients

R. Liu, Fei Ge, Chenxi Li, 2023, Journal of Cancer Research and Clinical Oncology.

Neoadjuvant checkpoint blockade in combination with Chemotherapy in patients with tripe-negative breast cancer: exploratory analysis of real-world, multicenter data

P. Qiu, Jieqiong Liu, Fei Xu, 2023, BMC Cancer.

An overview of the research progress of BRCA gene mutations in breast cancer.

Yi Zhang, and K. Wan, Guozhi Zhang, 2023, Biochimica et biophysica acta. Reviews on cancer.

Safety and feasibility assessment of extending the flushing interval in totally implantable venous access port flushing during the non-treatment stage for patients with breast cancer

Yi Zhang, Xianchun Chen, Ying Yang, 2022, Frontiers in Oncology.

Phase 2 study of anlotinib combined with taxanes and lobaplatin in the neoadjuvant treatment of triple-negative breast cancer: Efficacy, safety and biomarker analysis.

Jing Liu, Yi Zhang, L. Fan, 2022, Journal of Clinical Oncology.

Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is now

Yi Zhang, Juncheng Xuhong, X. Qi, 2023, Breast Cancer Research.

Docetaxel-loaded pH/ROS dual-responsive nanoparticles with self-supplied ROS for inhibiting metastasis and enhancing immunotherapy of breast cancer

Dinglin Zhang, F. Sun, Peiyuan Xia, 2023, Journal of Nanobiotechnology.

Application and prospect of organoid technology in breast cancer

X. Qi, Shanlin Huang, Zifan Mei, 2024, Frontiers in immunology.